PRINCETON, N.J. | January 5, 2026 — UroGen Pharma Ltd. has announced that a permanent HCPCS Level II J Code (J9282) for ZUSDURI™ (mitomycin) for intravesical solution is now in effect, marking a pivotal step in expanding patient access to an FDA-approved therapy for recurrent low-grade intermediate-risk non–muscle invasive bladder cancer (LG-IR-NMIBC). Effective January 1, 2026, the coding update is expected to streamline reimbursement and billing processes, reducing administrative barriers that often delay treatment initiation for cancer patients.
Science Significance
From a scientific and therapeutic perspective, ZUSDURI represents an important advance in the localized treatment of bladder cancer. The therapy combines mitomycin, a well-established chemotherapeutic agent, with UroGen’s proprietary RTGel® sustained-release hydrogel technology, enabling prolonged exposure of the bladder lining to the drug. This non-surgical chemoablative approach is designed to destroy tumors locally while minimizing systemic exposure. The significance lies in offering an alternative to repeated surgical interventions, which are common in this highly recurrent disease. By enhancing local drug delivery, ZUSDURI exemplifies how formulation science can improve the therapeutic profile of existing agents.
Regulatory Significance
The implementation of a permanent J Code is a critical regulatory and reimbursement milestone in the post-approval lifecycle of a prescription drug. Assigned by the Centers for Medicare & Medicaid Services (CMS), J9282 standardizes how ZUSDURI is billed across hospital outpatient departments and physician offices. This regulatory action does not change the drug’s clinical use but directly affects compliance, claims submission, and reimbursement predictability. For regulated stakeholders, it highlights how coding decisions can materially influence real-world access, reinforcing the importance of aligning regulatory approval with reimbursement infrastructure.
Business Significance
Advertisement
Commercially, the permanent J Code strengthens ZUSDURI’s market access and revenue visibility. Clear coding reduces administrative friction for providers, which can accelerate adoption and utilization. For UroGen, this milestone supports scalable commercialization in a specialty oncology market where treatment delays can hinder uptake. Predictable reimbursement pathways also improve payer engagement and financial forecasting, enhancing the long-term commercial sustainability of the product. In a competitive oncology landscape, efficient access mechanisms are often as important as clinical differentiation.
Patients’ Significance
For patients living with recurrent LG-IR-NMIBC, the impact is tangible. Bladder cancer frequently requires repeated procedures and ongoing surveillance, creating emotional, physical, and financial strain. By simplifying reimbursement, the permanent J Code helps ensure timely access to a nonsurgical treatment option, reducing delays that can exacerbate anxiety and disease burden. Importantly, broader access to ZUSDURI offers patients a chance to avoid or defer repeated surgeries, improving quality of life while maintaining disease control.
Policy Significance
At the policy level, the J Code designation underscores the role of reimbursement policy as a determinant of healthcare equity and innovation adoption. Even FDA-approved therapies may face limited uptake without clear billing mechanisms. This development illustrates how policy decisions translate scientific innovation into practical care delivery, particularly for older patient populations heavily reliant on Medicare coverage. It also reinforces the need for coordinated regulatory and reimbursement frameworks to support innovation in oncology.
The activation of a permanent J Code for ZUSDURI marks more than an administrative update; it represents a convergence of science, regulation, and patient access. By aligning FDA approval with streamlined reimbursement, UroGen Pharma has addressed a key barrier that often separates innovation from impact. For cGxP.wire readers, this milestone highlights how post-approval regulatory mechanisms are essential to realizing the full value of pharmaceutical innovation, ensuring that effective therapies reach patients without unnecessary delay.
Source: UroGen Pharma Ltd. press release
